Analyst Price Targets — IPSC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 12:24 pm | Daina Graybosch | Leerink Partners | $2.00 | $2.52 | StreetInsider | Leerink Partners Reiterates Market Perform Rating on Century Therapeutics (IPSC) |
| January 20, 2026 11:50 am | — | Piper Sandler | $4.00 | $2.17 | TheFly | Century Therapeutics price target raised to $4 from $2 at Piper Sandler |
| November 6, 2024 11:41 am | Mitchell Kapoor | H.C. Wainwright | $5.00 | $1.39 | StreetInsider | Century Therapeutics (IPSC) PT Lowered to $5 at H.C. Wainwright |
| April 12, 2024 7:02 am | Edward Tenthoff | Piper Sandler | $9.00 | $4.05 | StreetInsider | Century Therapeutics (IPSC) PT Lowered to $9 at Piper Sandler |
| January 5, 2023 9:48 pm | Edward Tenthoff | Piper Sandler | $14.00 | $4.84 | TheFly | Century Therapeutics price target lowered to $14 from $24 at Piper Sandler |
| December 27, 2022 5:35 am | Geulah Livshits | Chardan Capital | $19.00 | $5.67 | TheFly | Century Therapeutics initiated with a Buy at Chardan |
| November 14, 2022 6:24 am | — | H.C. Wainwright | $25.00 | $11.00 | Benzinga | HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $25 |
| April 29, 2022 5:38 am | — | Leerink Partners | $27.00 | $12.03 | Benzinga | SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $27 |
Latest News for IPSC
Shares of Century Therapeutics, Inc. (NASDAQ: IPSC - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy
PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will participate in the following upcoming investor conferences in March:
Hikma Pharmaceuticals (OTCMKTS:HKMPF - Get Free Report) and Century Therapeutics (NASDAQ: IPSC - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Analyst Ratings This is a summary of current
The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and commercial analysis. The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics,…
Century Therapeutics is positioned as a leading contender in developing a durable, once-and-done cure for type I diabetes mellitus (T1DM) using its hypoimmune iPSC-derived β-cell therapy, CNTY-813. IPSC's Allo-Evasion platform uniquely targets T-cell, NK-cell, and humoral immunity, potentially offering superior long-term engraftment and immune escape versus competitors like SANA, VRTX, and CRSP. With cash runway to…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IPSC.
U.S. House Trading
No House trades found for IPSC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.